Cipla (CIPLA)

FairStock Score: 62/100 — STEADY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Strong ROCE of 22.7% indicating efficient capital utilization
• Established pharmaceutical company with large market presence
• Consistent dividend paying track record in pharma sector

Concerns

• Sharp profit decline of 43.7% threatening dividend sustainability
• Zero sales growth indicating competitive challenges
• Low DhanIQ score of 2/10 reflecting weak overall metrics

AI Analysis

Cipla is a Slow Grower company — a pharmaceutical giant with a market cap of Rs 1.1 lakh crores trading at Rs 1,300 per share. For dividend-focused investors, the current picture presents mixed signals. The company offers a 1% dividend yield, which is modest but represents income from a well-established pharmaceutical business. However, the data indicates significant challenges that may impact dividend sustainability. Cipla's profit growth shows a concerning decline of 43.7%, while sales growth stands flat at 0%. This combination suggests the company is facing operational headwinds that could pressure its ability to maintain consistent dividend payments. On the positive side, Cipla maintains a healthy ROCE of 22.7%, indicating efficient capital utilization despite current challenges. The P/E ratio of 22.9 reflects market expectations, though the DhanIQ score of 2 out of 10 signals weak overall performance metrics. Analysis suggests that while Cipla's dividend yield provides some income, investors may consider the sustainability risks given the declining profitability trend. The flat sales growth in a growing healthcare market raises questions about the company's competitive positioning and future dividend coverage.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer